AV网在线不卡免费看|AV最新网址在线免费|a在线免费观看网站|yy6080亚洲人久久精品

擅長(zhǎng)領(lǐng)域：肝腫瘤的診治及肝移植。 長(zhǎng)期從事肝癌及肝移植的臨床和基礎(chǔ)研究工作，已積累1000余例肝切除和300余例肝移植臨床經(jīng)驗(yàn)，能夠成功施行過(guò)去視為禁區(qū)的合并門(mén)靜脈主干癌栓肝癌、尾狀葉肝癌、巨大肝癌和侵犯下腔靜脈的肝癌等手術(shù)以及肝臟移植手術(shù)。?

執(zhí)業(yè)經(jīng)歷： 專(zhuān)長(zhǎng)肝腫瘤的診治及肝移植。 長(zhǎng)期從事肝癌及肝移植的臨床和基礎(chǔ)研究工作，已積累1000余例肝切除和300余例肝移植臨床經(jīng)驗(yàn)，能夠成功施行過(guò)去視為禁區(qū)的合并門(mén)靜脈主干癌栓肝癌、尾狀葉肝癌、巨大肝癌和侵犯下腔靜脈的肝癌等手術(shù)以及肝臟移植手術(shù)。 　　學(xué)術(shù)任職國(guó)際外科醫(yī)師和胃腸病學(xué)家委員會(huì)(IASGO)會(huì)員?！癊xpert Opinion On Drug Metabolism and Toxicology” “中華實(shí)驗(yàn)外科雜志”等雜志審稿專(zhuān)家。 　　研究方向肝癌的早起發(fā)生以及肝癌切除術(shù)后或肝移植術(shù)后轉(zhuǎn)移復(fù)發(fā)的分子機(jī)制及防治 　　教學(xué)工作為本科生上大課4學(xué)時(shí);協(xié)助指導(dǎo)碩士研究生3名、博士研究生2名。 　　所獲獎(jiǎng)項(xiàng)獲國(guó)家科技進(jìn)步二等獎(jiǎng)及上海市科技進(jìn)步一等獎(jiǎng)(第五完成人)各一項(xiàng)。 　　基本課題獲國(guó)家自然科學(xué)基金 2項(xiàng)，上海市自然科學(xué)基金 1項(xiàng)。 　　論文1) Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang XW, Tang ZY. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res. 2008; 14(16):5124-30. IF=7.837 2) Wang Z, Hu J, Qiu SJ, Huang XW, Dai Z, Tan CJ, Zhou J, Fan J. An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels. Expert Opin Investig Drugs. 2011; 20(8):1039-45. IF=4.744 3) Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang XW, Sun J, Tan CJ, Dai Z. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth. Expert Opin Investig Drugs. 2009; 18(11):1595-604. IF=4.744 4) Wang Z, Zhou J, Fan J, Tan CJ, Qiu SJ, Yu Y, Huang XW, Tang ZY. Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009; 135(5):715-22. IF=2.914 5) Hu J, Wang Z(共同第一), Liao BY, Yu L, Gao X, Lu S, Wang S, Dai Z, Zhang X, Chen Q, Qiu SJ, Wu Y, Zhu H, Fan J, Zhou J, Wang J.Human miR-1228 as a stable endogenous control for the quantification of circulating microRNAs in cancer patients. Int J Cancer. 2014 Feb 1. doi: 10.1002/ijc.28757. [Epub ahead of print] IF=6.198 6) Hu J, Wang Z(共同第一), Tang CJ, Liao BY, Xu M, Dai Z, Qiu SJ, Huang XW, Sun J, Sun QM, He YF, Song K, Pan Q, Wu Y, Fan J, Zhou J. Plasma microRNA, a potential biomarker for acute rejection after liver transplantation. Transplantation. 2013; 27; 95(8):991-9. IF=3.781 7) Hu J, Wang Z (共同第一), Fan J, Dai Z, He YF, Qiu SJ, Huang XW, Sun J, Xiao YS, Song K, Shi YH, Sun QM, Yang XR, Shi GM, Yu L, Yang GH, Ding ZB, Gao Q, Tang ZY, Zhou J. Genetic variations in plasma circulating DNA of HBV-related hepatocellular carcinoma patients predict recurrence after liver transplantation. PLoS One. 2011; 6(10):e26003. IF=3.73 詳細(xì)介紹